Pfizer Oncology Strategy: An Investment Starts To Pay Off
Executive Summary
With the launch of Ibrance and a burgeoning immuno-oncology program, Pfizer’s oncology business is on track to generate substantial revenue and investors are starting to take note. Oncology President Liz Barrett and Chief Medical Officer Mace Rothenberg discuss Pfizer’s initiative to become a leader in the field.
You may also be interested in...
Pfizer Oncology Strategy: Keeping Pace In The Doublet/Triplet IO Race
Pfizer has seven immuno-oncology drugs in the clinic and an ambition to be the first drug maker to bring a PD-1/OX40/4-1BB triplet regimen into the clinic late this year or early next.
With The End Of Pfizergan, Pfizer Has To Grow It Alone
Investors are wondering what Pfizer might do next – and especially whether or not it will split – after the company is outmaneuvered by the US government and ends its ambition to merge with Allergan.
Among New Drug Launches, Oncology Scores Big While CV Lags
Bristol’s Opdivo and Pfizer’s Ibrance are standouts among recent drug launches, well on their way to becoming commercial blockbusters, while new cardiovascular drugs like Repatha, Praluent and Entresto, forecast to become blockbusters in their own right, have been slow at launch, restrained by market access.